The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were used to study PD-1/PD-L1 expression. Functional assays were used to determine the involvement of the PD-1/PD-L1 axis in T-cell responses. PD-1 expression by CD4(+) and CD8(+) T lymphocytes was significantly higher in 117 chronic lymphocytic leukemia patients than in 33 donors of a comparable age. CD4(+) and CD8(+) T lymphocytes from chronic lymphocytic leukemia patients displayed increased numbers of effector memory and terminally differentiated cells, respectively, when compared to controls. The number of effector memory CD4(+) and terminally differentiated CD8(+) lymphocytes positively associated with a more advanced stage of disease, treatment requirements and unfavorable genomic aberrations. Furthermore, leukemic lymphocytes expressed higher levels of PD-L1 than circulating B lymphocytes from normal donors. PD-1 and PD-L1 surface expression spiked in proliferating T and B lymphocytes, suggesting that this interaction works efficiently in activated environments. Within chronic lymphocytic leukemia proliferation centers in the lymph node, CD4(+)/PD-1(+) T lymphocytes were found to be in close contact with PD-L1(+) chronic lymphocytic leukemia cells. Lastly, functional experiments using recombinant soluble PD-L1 and blocking antibodies indicated that this axis contributes to the inhibition of IFN-γ production by CD8(+) T cells. These observations suggest that pharmacological manipulation of the PD-1/PD-L1 axis may contribute to restoring T-cell functions in the chronic lymphocytic leukemia microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Targeting this receptor-ligand pair using specific antibody therapy leads to impressive clinical responses in patients with solid tumors of different origins.(34,35) On the contrary, data and information on the expression and function of PD-1 and its ligands in normal and neoplastic lymphoid tissues is more limited.”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“Even if this is more effective in the early stages of tumorigenesis, there is ample evidence to suggest that during progression tumor cells continue to exploit a wide variety of subversive processes aimed at maintaining their own survival.(31) At least in solid tumors, one such process relies on the overexpression of…”
BackgroundThe PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300 · cited 2×
“On the contrary, PD1 is classically considered a marker of cell exhaustion in the CD8 subset.(21) Thus, the finding of an increased expression of PD-1 in T lymphocytes from CLL patients suggests a relative enrichment in terminally differentiated cells as compared to controls with a similar age.”
BackgroundGood-Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M., & Shlomchik, M. J. (2010) · Nature Immunology · doi:10.1038/ni.1877 · Cited by 691
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600 · cited 1×
“CD4 and CD8 T lymphocytes from CLL patients show distinct gene profiles,(13) with alterations in multiple genetic pathways, including the actin cytoskeleton.(14) Functional studies confirmed that these T cells have defects in F-actin polymerization and immune synapse formation with antigen presenting cells, both essen…”
BackgroundFrom pathogenesis to treatment of chronic lymphocytic leukaemia
Zenz, T., Mertens, D., Küppers, R., Döhner, H., & Stilgenbauer, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2764 · Cited by 553 · cited 1×
“Distinct receptor-ligand pairs, as well as soluble molecules mediating crosstalk between CLL cells and stromal-derived elements, are attracting increasing attention as potential therapeutic targets.(3,4) In addition, several lines of evidence indicate that CLL development and progression is accompanied by a progressiv…”
BackgroundEndothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali, M.-A. A., Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2046 · Cited by 484
PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T., et al. (2008) · Blood · doi:10.1182/blood-2007-05-085159 · Cited by 401
Ramsay, A. G., Clear, A. J., Fatah, R., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-02-411678 · Cited by 358
Dorfman, D. M., Brown, J. A., Shahsafaei, A., & Freeman, G. J. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000209855.28282.ce · Cited by 358 · cited 2×
“Reactive LN samples with clearly identifiable and conserved follicles were characterized by a subset of predominantly small lymphocytes in the germinal centers showing intense staining for PD-1, in line with previous data.(27,28) PD-1 staining was also apparent in the interfollicular areas, predominantly containing T…”
BackgroundResultB7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis
Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 326 · cited 1×
“On the contrary, PD-L1 staining in reactive LN samples was mostly associated with endothelial cells lining small vessels.(40,41) In the same samples, follicular T-helper cells of CD4 origin were clearly PD-1.”
ResultChronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
Görgün, G., Holderried, T. A. W., Zahrieh, D., Neuberg, D., & Gribben, J. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24176 · Cited by 298 · cited 1×
“CD4 and CD8 T lymphocytes from CLL patients show distinct gene profiles (13), with alterations in multiple”
Dicker, F., Schnittger, S., Haferlach, T., Kern, W., & Schoch, C. (2006) · Blood · doi:10.1182/blood-2006-02-005322 · Cited by 223
Bagnara, D., Kaufman, M. S., Calissano, C., Marsilio, S., Patten, P. E. M., Simone, R., Chum, P., Yan, X.-J., Allen, S. L., Kolitz, J. E., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324210 · Cited by 221 · cited 1×
“In addition, the success of CLL engraftment and growth in an immunodeficient mouse was found to be selectively dependent on activated autologous T lymphocytes, implying that this population is essential for in vivo neoplastic cell survival and proliferation.(11) The mechanisms responsible for T-cell dysfunction in CLL…”
BackgroundCD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.
Patten, P. E. M., Buggins, A. G. S., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G. J., Hamblin, T. J., & Devereux, S. (2008) · Blood · doi:10.1182/blood-2007-08-108605 · Cited by 196
Caligaris-Cappio, F., & Ghia, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4393 · Cited by 194 · cited 1×
“It is now largely accepted that chronic lymphocytic leukemia (CLL) fits best the model of a compartmentalized disease, with the proliferative component localized almost exclusively in lymphoid organs.(1,2) Here, environmental interactions appear to fine tune the competence of leukemic cells to survive, grow and eventu…”
BackgroundXerri, L., Chetaille, B., Seriari, N., Attias, C., Guillaume, Y., Arnoulet, C., & Olive, D. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.11.012 · Cited by 172 · cited 1×
“Reactive LN samples with clearly identifiable and conserved follicles were characterized by a subset of predominantly small lymphocytes in the germinal centers showing intense staining for PD-1, in line with previous data.(27,28) PD-1 staining was also apparent in the interfollicular areas, predominantly containing T…”
ResultChen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., & Zhang, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.10.016 · Cited by 164
Abnormal T-cell Function in B-cell Chronic Lymphocytic Leukaemia
Scrivener, S., Goddard, R. V., Kaminski, E. R., & Prentice, A. G. (2003) · Leukemia & Lymphoma · doi:10.1080/1042819021000029993 · Cited by 164
Nunes, C., Wong, R., Mason, M. D., Fegan, C., Man, S., & Pepper, C. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2630 · Cited by 156
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies, D. B., Sandler, B. J., Sznol, M., & Chen, L. (2011) · PubMed Central · Cited by 154
Shimatani, K., Nakashima, Y., Hattori, M., Hamazaki, Y., & Minato, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908805106 · Cited by 132
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L., Egle, A., Hartmann, T. N., & Greil, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.72 · Cited by 125 · cited 1×
“Distinct receptor-ligand pairs, as well as soluble molecules mediating crosstalk between CLL cells and stromal-derived elements, are attracting increasing attention as potential therapeutic targets.(3,4) In addition, several lines of evidence indicate that CLL development and progression is accompanied by a progressiv…”
BackgroundRichendollar, B. G., Pohlman, B. L., Elson, P. J., & Hsi, E. D. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.08.015 · Cited by 110
Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia
González, A. P., Contesti, J., Huergo-Zapico, L., López‐Soto, A., Fernández-Guizán, A., Acebes‐Huerta, A., González‐Huerta, A. J., González, E., Fernández-Álvarez, C., & Gonzalez, S. R. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.503820 · Cited by 107 · cited 1×
“cent of the clinical picture described for patients with chronic infections.(6,12) CD4 and CD8 T lymphocytes from CLL patients show distinct gene profiles,(13) with alterations in multiple genetic pathways, including the actin cytoskeleton.”
BackgroundShimauchi, T., Kabashima, K., Nakashima, D., Sugita, K., Yamada, Y., Hino, R., & TOKURA, Y. (2007) · International Journal of Cancer · doi:10.1002/ijc.23042 · Cited by 105
Adékambi, T., Ibegbu, C., Kalokhe, A. S., Yu, T., Ray, S. M., & Rengarajan, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036046 · Cited by 102
Soma, L. A., Craig, F. E., & Swerdlow, S. H. (2006) · Human Pathology · doi:10.1016/j.humpath.2005.09.029 · Cited by 101 · cited 1×
“Histological studies of CLL lymph node (LN) samples have shown that within the proliferation centers (PC) [the counterpart of germinal centers (9)], leukemic cells are in close contact with a population of CD4/CD25/Foxp3 T lymphocytes (10).”
Scrivener, S. G., Kaminski, E. R., Demaine, A. G., & Prentice, A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02672.x · Cited by 85 · cited 4×
“For this reason, PD-1 and PD-L1 expression patterns were tested by immunohistochemistry and confocal microscopy in LN specimens obtained from 20 patients with a confirmed diagnosis of CLL.”
BackgroundInfluentialGrzywnowicz, M., Zaleska, J., Mertens, D., Tomczak, W., Własiuk, P., Kosior, K., Piechnik, A., Bojarska-Junak, A. A., Dmoszyńska, A., & Giannopoulos, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035178 · Cited by 82 · cited 3×
“A fraction of circulating CLL cells is also reported as PD-1 (see Grzywnowicz et al.(17) and Li et al.”
BackgroundResultInfluentialBrusa, D., Garetto, S., Chiorino, G., Scatolini, M., Migliore, E., Camussi, G., & Matera, L. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.063 · Cited by 66
Self-citationDorfman, D. M., & Shahsafaei, A. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31820065c9 · Cited by 58 · cited 1×
“In the same samples, follicular T-helper cells of CD4 origin were clearly PD-1.(42) Thus, at least within the LN and with the limits of these techniques, the paradigm seems to be that CD4/PD-1 T lymphocytes interact with CD23/PDL1 leukemic B cells, and this occurs specifically in the CLL LN.”
BackgroundPorakishvili, N., Roschupkina, T., Kalber, T. L., Jewell, A. P., Patterson, K. G., Yong, K., & Lydyard, P. M. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01639.x · Cited by 58
Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways
Wang, S., & Chen, L. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_81 · Cited by 53 · cited 1×
“At least in solid tumors, one such process relies on the overexpression of the surface molecule PD-L1, which can engage the co-receptor PD-1 on surrounding T lymphocytes and inhibit T cell responses, consequently permitting cancer progression and diffusion (32, 33).”
Li, M., Sun, X., Zhu, X., Jin, S.-G., Zeng, Z.-J., Zhou, Z., Yu, Z., & Gao, Y. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.157 · Cited by 44
Monteiro, M., Evaristo, C., Legrand, A., Nicoletti, A., & Rocha, B. (2007) · Blood · doi:10.1182/blood-2006-06-027060 · Cited by 42
Shen, T., Zheng, J., Liang, H. L., Xu, C., Chen, X., Zhang, T., Xu, Q., & Lu, F. (2011) · Virology Journal · doi:10.1186/1743-422x-8-279 · Cited by 41
Structure and function of the hematopoietic cancer niche focus on chronic lymphocytic leukemia
Kipps, T. J. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s251 · Cited by 35
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia
Jessi, F. F. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/251 · Cited by 28 · cited 1×
“It is now largely accepted that chronic lymphocytic leukemia (CLL) fits best the model of a compartmentalized disease, with the proliferative component localized almost exclusively in lymphoid organs.(1,2) Here, environmental interactions appear to fine tune the competence of leukemic cells to survive, grow and eventu…”
BackgroundWalton, J. A., Lydyard, P. M., Nathwani, A. C., Emery, V. C., Akbar, A. N., Glennie, M. J., & Porakishvili, N. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07964.x · Cited by 19
Ellis, J. S., Guloglu, F. B., Tartar, D. M., Hoeman, C. M., Haymaker, C., Cascio, J. A., Wan, X., Dhakal, M., VanMorlan, A. M., Yahng, S.-H., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000810 · Cited by 8
Cited by
Choo, Y. W., Kang, M., Kim, H. Y., Han, J., Kang, S., Lee, J.-R., Jeong, G.-J., Kwon, S. P., Song, S. Y., Go, S., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b02446 · Cited by 465
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
Ibrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
Perturbation of the normal immune system in patients with CLL
Forconi, F., & Moss, P. (2015) · Blood · doi:10.1182/blood-2015-03-567388 · Cited by 385
Mueller, K. T., Maude, S. L., Porter, D. L., Frey, N., Wood, P., Han, X., Waldron, E., Chakraborty, A., Awasthi, R., Levine, B. L., et al. (2017) · Blood · doi:10.1182/blood-2017-06-786129 · Cited by 362
Metadata
- Authors
- Brusa, D., Serra, S., Coscia, M., Rossi, D., D'Arena, G., Laurenti, L., Jaksic, O., Fedele, G., Inghirami, G., Gaidano, G., Malavasi, F., & Deaglio, S.
- Venue
- Haematologica
- Published
- 2013-01-08
- Volume
- 98
- Issue
- 6
- Pages
- 953-963
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2020586896
- Cited by
- 222
- References
- 44
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.